| ARBUTUS BIOPHARMA |
| Kanada |
| Gesundheit |
| CA03879J1003 / A14XMD |
| I9DN (Frankfurt) / ABUS (NASDAQ) |
| FRA:I9DN, ETR:I9DN, I9DN:GR, NASDAQ:ABUS |
| - |
| https://www.arbutusbio.co.. |
|
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in virology with a focus on developing novel therapeutics for infectious diseases, particularly chronic hepatitis B virus (cHBV). The company leverages its deep ..
>Volltext.. |
| 819.92 Mio. EUR |
| 742.7 Mio. EUR |
| 155.6 Mio. EUR |
| 126.27 Mio. EUR |
| 131.05 Mio. EUR |
| 0.68 EUR |
| 3.1 Mio. EUR |
| 16.42 Mio. EUR |
| -20.66 Mio. EUR |
| 27.53 |
| 1115.86% |
| - |
| - |
| - |
| - |
| - |
| ARBUTUS |
| 21.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|